<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03967470</url>
  </required_header>
  <id_info>
    <org_study_id>CMET</org_study_id>
    <nct_id>NCT03967470</nct_id>
  </id_info>
  <brief_title>Bacteriotherapy to Improve Underarm Odor</brief_title>
  <official_title>Bacteriotherapy to Improve Underarm Odor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Ghent</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal is to improve the underarm odor by changing the microbiome. The autochthonous
      bacterial community is replaced by a non-smelling microbiome, by daily application of
      bacteria in a spray.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants are recruited and selected based on their initial underarm odor and underarm
      microbiome. The participants use two sprays: one spray containing the bacteria, and the other
      nothing (placebo). Participants do not know which spray they have. They use one spray during
      one month, and meanwhile take samples of their underarm microbiome (for sequencing), volatome
      (for GC/MS analysis) and odor (for odor panel analysis). Samples are stored in the freezer
      and brought to the university after one month, when they receive the second spray. The
      bacterial spray contains bacteria that are correlated with good underarm odor.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>two groups of 30 people, one month of bacterial spray use and the other month placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Double blind: participants nor outcome assessors, odor panel or care providers do not know which spray they use.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Improved underarm odor</measure>
    <time_frame>1 month</time_frame>
    <description>Odor panel and GC/MS results provide insights on underarm odor development</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Bromhidrosis</condition>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo spray used during one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bacteria spray used during one month</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bacterial spray</intervention_name>
    <description>Bacterial spray containing bacteria that do not cause underarm malodor</description>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  above average underarm malodor

          -  microbiome dominated with malodorous bacteria

        Exclusion Criteria:

          -  not healthy

          -  microbiome with too high levels of Staphylococcus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Van de Wiele, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ghent University</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.drarmpit.com</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Callewaert C, Lambert J, Van de Wiele T. Towards a bacterial treatment for armpit malodour. Exp Dermatol. 2017 May;26(5):388-391. doi: 10.1111/exd.13259. Epub 2017 Feb 2.</citation>
    <PMID>27892611</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>May 27, 2019</last_update_submitted>
  <last_update_submitted_qc>May 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All data remain confidential</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

